Agile Therapeutics (AGRX) Q2 2024 earnings summary

Executive summary

• Agile Therapeutics focuses on commercializing Twirla, a once-weekly contraceptive patch, and is advancing a merger with Insud Pharma, S.L. that will convert shares to $1.52 in cash if approved.

• The company reported continued operating losses and negative cash flows, with an accumulated deficit of $433.8 million as of June 30, 2024.

• Liquidity remains a concern, with $2.8 million in cash and cash equivalents, sufficient to fund operations only into September 2024 absent the merger.

• The merger is expected to close in Q3 2024, subject to shareholder approval and other customary conditions.

Financial highlights

• Q2 2024 net revenue was $5.6 million, up 1% year-over-year; unit sales rose 1% to 62,346.

• Gross profit for Q2 2024 was $4.1 million, up from $3.2 million in Q2 2023.

• Net loss for Q2 2024 was $11.9 million, compared to $3.8 million in Q2 2023, driven by a $9.2 million non-cash loss on warrant liability.

• For the six months ended June 30, 2024, net revenue was $11.3 million (up 21% year-over-year), with a net loss of $10.6 million.

• Operating expenses for Q2 2024 were $6.8 million, down 18% from Q2 2023, reflecting cost reductions in R&D, selling, and G&A.

Outlook and guidance

• Management expects continued operating losses and negative cash flows as Twirla commercialization continues.

• If the merger is not completed, the company may need to seek bankruptcy protection or raise additional capital under challenging conditions.

• The company is focused on expanding Twirla’s market reach, improving reimbursement, and managing costs.